CVS will reinstate Zepbound coverage starting October 1, 2026, and begin covering Foundayo on June 1, 2026.
Both Lilly's and Novo Nordisk's GLP-1 medications will be co-preferred options on CVS Caremark's standard commercial formulary.
This decision aims to provide more affordable and optional weight-loss drug choices for customers.
Employers are grappling with rising healthcare costs, with pharmacy expenses increasing nearly 15% in 2026 due to GLP-1 medications.
CVS expects this expanded coverage to drive an additional 10% to 15% savings across the weight management category.
Why this matters: This decision by CVS significantly impacts access to weight-loss treatments, offering millions of Americans more choices and potentially driving down costs through increased competition among drug manufacturers. It also reflects the growing pressure on employers to manage rising healthcare expenses.
CVS Caremark's decision to reinstate Zepbound and add Foundayo reflects a strategic effort to balance cost management with patient access to effective weight-loss medications. This move comes a year after CVS initially favored Novo Nordisk's Wegovy, indicating a shift towards a more competitive landscape. The inclusion of both Lilly and Novo Nordisk drugs as co-preferred options on the standard formulary means that insurers and employers can choose to adopt these options, impacting approximately 25 million to 30 million Americans.
The rising cost of healthcare, particularly pharmacy expenses driven by GLP-1 medications, is a significant concern for employers. By negotiating more affordable costs with manufacturers, CVS aims to alleviate some of this financial pressure while providing valuable treatment options.
Actionable Takeaways:
Check with your insurance provider or employer to see if Zepbound and Foundayo are covered under your plan.
Consult with your doctor to determine the most appropriate weight-loss treatment option for you.
Be aware that coverage may vary depending on the specific formulary adopted by your employer or insurer.
Q: When will CVS start covering Zepbound and Foundayo?
Zepbound coverage begins October 1, 2026, and Foundayo coverage starts June 1, 2026.
Q: Will my insurance cover these weight-loss drugs?
Coverage depends on whether your employer or insurer adopts CVS Caremark's standard formulary and whether they opt to include GLP-1 medications for weight loss.
Q: Are there alternative ways to access these medications if my insurance doesn't cover them?
Yes, Novo and Lilly have slashed prices for consumers whose insurance plans don't cover weight-loss medications. Cash-paying customers can buy Wegovy or Zepbound from the pharmaceutical companies, telehealth portals, or retailers.
CVS is expanding coverage to include both Zepbound and Foundayo, offering more weight-loss treatment choices.
This move aims to drive competition and affordability in the weight-loss drug market.
Employers and insurers play a key role in determining coverage for these medications.
Rising healthcare costs are a concern, but CVS is working to negotiate better prices with manufacturers.
What are your thoughts on CVS's decision to expand coverage for weight-loss drugs? Share your experiences and opinions in the comments below!
Share this article with others who need to stay ahead of this trend!
Novo Nordisk is broadening its research into semaglutide, originally developed for diabetes and obesity, to explore its potential in treatin...
After more than four decades, a new prescription medicine has emerged to combat motion sickness. Vanda Pharmaceuticals has announced the U.S...
Two major pharmaceutical companies, AbbVie and Genentech, are set to launch their medications on the TrumpRx platform, offering discounted p...
Johnson & Johnson's Icotyde (icotrokinra) has secured FDA approval, marking a significant advancement in psoriasis treatment. This first-of-...
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer